Plain-English translation of NCT07209059 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
The FINISH study is testing a new way to treat advanced Hodgkin lymphoma using a medication called combined with chemotherapy. After the first two rounds of treatment, doctors use PET scans to see how well the cancer is responding, and then customize the next phase of treatment based on those results. The goal is to give patients the most effective treatment while reducing long-term side effects.
Current standard treatments for advanced Hodgkin lymphoma can work well but sometimes cause serious long-term health problems. This trial is exploring whether the new medication, guided by early scan results, can help doctors give just the right amount of treatment—no more, no less—so patients get better outcomes with fewer lasting side effects.
You likely qualify if…
You likely don't qualify if…
You will receive the new immunotherapy medication combined with chemotherapy over two initial cycles, with regular clinic visits and blood work. After two cycles, you'll have a PET scan to see how well the treatment is working. Based on those results, your doctor will either reduce the intensity of your remaining treatment or continue at the current level. Throughout the trial, you'll also have blood samples taken at certain timepoints to help researchers understand how your body is responding at a molecular level. The total treatment period will span several months with ongoing follow-up visits.
AI-generated summary from trial data · Nov 17, 2026 · Not medical advice
Russia